Frontiers in Pharmacology (Dec 2021)

Proteomics Analysis of Tears and Saliva From Sjogren’s Syndrome Patients

  • Nabangshu Das,
  • Nabangshu Das,
  • Nikhil G. Menon,
  • Luiz G. N. de Almeida,
  • Luiz G. N. de Almeida,
  • Paige S. Woods,
  • Miriam L. Heynen,
  • Gregory D. Jay,
  • Barbara Caffery,
  • Lyndon Jones,
  • Roman Krawetz,
  • Roman Krawetz,
  • Tannin A. Schmidt,
  • Tannin A. Schmidt,
  • Antoine Dufour,
  • Antoine Dufour,
  • Antoine Dufour

DOI
https://doi.org/10.3389/fphar.2021.787193
Journal volume & issue
Vol. 12

Abstract

Read online

Sjogren’s syndrome (SS) is characterized by dysfunctional mucous membranes and dysregulated moisture-secreting glands resulting in various symptoms, including dry mouth and dry eyes. Here, we wanted to profile and compare the tear and saliva proteomes of SS patients to healthy controls. Tear and saliva samples were collected and subjected to an isotopic dimethylation labeling shotgun proteomics workflow to identify alterations in protein levels. In tear samples, we identified 83 upregulated and 112 downregulated proteins. Pathway enrichment analysis of the changing proteins by Metascape identified leukocyte transendothelial migration, neutrophil degranulation, and post-translation protein phosphorylation in tears of SS patients. In healthy controls’ tears, an enrichment for proteins related to glycolysis, amino acid metabolism and apoptotic signaling pathway were identified. In saliva, we identified 108 upregulated and 45 downregulated proteins. Altered pathways in SS patients’ saliva included cornification, sensory perception to taste and neutrophil degranulation. In healthy controls’ saliva, an enrichment for proteins related to JAK-STAT signaling after interleukin-12 stimulation, phagocytosis and glycolysis in senescence were identified. Dysregulated protease activity is implicated in the initiation of inflammation and immune cell recruitment in SS. We identified 20 proteases and protease inhibitors in tears and 18 in saliva which are differentially expressed between SS patients and healthy controls. Next, we quantified endogenous proteoglycan 4 (PRG4), a mucin-like glycoprotein, in tear wash and saliva samples via a bead-based immune assay. We identified decreased levels of PRG4 in SS patients’ tear wash compared to normal samples. Conversely, in saliva, we found elevated levels of PRG4 concentration and visualized PRG4 expression in human parotid gland via immunohistological staining. These findings will improve our mechanistic understanding of the disease and changes in SS patients’ protein expression will help identify new potential drug targets. PRG4 is among the promising targets, which we identified here, in saliva, for the first time.

Keywords